Reply  by McNamara, Dennis M. et al.
p
M
d
i
o
r
I
f
p
f
h
d
Journal of the American College of Cardiology Vol. 59, No. 8, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc.CORRESPONDENCELetters to the Editor
i
c
t
c
c
i
*
*
1
4
C
E
RA New Era in the
Natural History of
Dilated Cardiomyopathy
I read with interest the paper by McNamara et al. (1), which
supports the findings of our previous report of a logistic model that
identifies factors associated with restoration of normal ventricular
function in this patient population (2). As we noted in that paper,
which indeed references the marked improvement in left ventric-
ular function observed in the placebo group of the IMAC
(Intervention in Myocarditis and Acute Cardiomyopathy) trial, we
have entered a new era in the natural history of dilated cardiomy-
opathy in which restoration of normal ventricular function may be
anticipated in a significant number of patients. This demands that
we better identify those patients who are likely to recover normal
ventricular function. Identification of those who have a high
probability of recovery will allow early implementation of more
aggressive therapies in those who are not likely to recover, and will
point towards interventions that may augment the factors found to
be associated with restoration of normal ventricular function.
In particular, our report identified progressive increases in QRS
duration, male gender, ischemic etiology of heart failure, and a
history of diabetes mellitus as factors that decrease the probability
of recovery. The probability of recovery increased with increasing
systolic blood pressure at the time of initial diagnosis. Indeed, the
report by McNamara et al. (1) is in agreement with 3 of these
factors. They also find that female gender and increasing blood
pressure are associated with recovery of ventricular function.
Electrocardiographic QRS duration is known to correlate highly
with ventricular chamber size, and therefore, it is not surprising
that they find end-diastolic dimension to be a significant correlate
with ventricular recovery. The cohort in their study did not strictly
match that in our study, being focused on those with recent-onset
cardiomyopathy. They specifically excluded patients with ischemic
heart disease and diabetes, and therefore, our data provide insight
into different etiologies of cardiomyopathy and the important
comorbidity of diabetes. In addition, the average time to recovery
of left ventricular function in our study was 40.3  4.7 months,
roviding total patient-years equivalent to that in the study by
cNamara et al. (1), even though our cohort size was smaller. Our
ata show that recovery can be a slow process, and it would be
nteresting to see how the factors they identify influence recovery
ver longer periods of time.
The recognition that patients with dilated cardiomyopathy can
ecover normal ventricular function raises important questions.
mportantly, it is unknown whether return to normal ventricular
unction represents a true recovery from the cardiomyopathic
rocess or is in fact a “remission” with persistence of normal
unction dependent on continued medical therapy. Indeed, we
ave reported a small series of patients who have “relapsed” with
iscontinuation of medical therapy (3). Should the current Amer-can Heart Association/American College of Cardiology classifi-
ation of heart failure stage include a new category designating
hose who have returned to normal cardiac function? As we
ontinue to understand this new era in the natural history of
ardiomyopathy, we are challenged to address these and other
ssues.
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Reply
We certainly agree that several of the same factors appear to
predict recovery in both the IMAC2 (Intervention in Myocarditis
and Acute Cardiomyopathy 2) trial (1) and the cohort reported by
Dr. Binkley and his colleagues (2). Indeed, consistent with the
Ohio State report, in unpublished data from IMAC2, subjects
with a left bundle branch block (LBBB) at presentation had a
significantly lower left ventricular ejection fraction (LVEF) at 6
months (with LBBB, mean LVEF: 0.38  0.12; no LBBB:
0.41  0.12, p  0.04) and a trend toward less improvement in
LVEF (with LBBB, change in LVEF from entry to 6 months:
0.14  0.14; no LBBB: 0.18  0.12, p  0.07). Although only
19% of IMAC2 subjects had LBBB at presentation, 54% had
evidence of dyssynchrony by speckle tracking imaging despite a
narrow QRS (3). This declined to 12% by 6 months, and the
restoration of synchrony may indeed have played a role in subse-
quent myocardial recovery.
As suggested, QRS duration may also be a surrogate for
remodeling. The finding in IMAC2 that greater remodeling (as
defined by left ventricular end-diastolic diameter [LVEDD])
predicts less recovery has also been reported by Simon et al. (4) for
a cohort of subjects on LV assist device support, and indeed was
previously evident in the first IMAC trial (5). LVEDD appears to
be a consistent clinical tool for predicting myocardial recovery.
Whether the impact of QRS duration on myocardial recovery
RR
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February 21, 2012:776–8reflects an association with remodeling or a primary role of
dyssynchrony itself remains to be determined.
The consistency of these clinical characteristics for predicting
recovery, in particular gender, QRS duration, and the degree of
remodeling (LVEDD), does support the concept of a “recovery
score” advocated by the Ohio State group. If prospectively vali-
dated, this would be of great assistance to clinicians in the
management of subjects with recent-onset cardiomyopathy. We
thank Dr. Binkley for his insightful comments.
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Angiotensin-Converting Enzyme
Inhibitors Can Increase the
Transvalvular Gradient Among
Patients With Aortic Stenosis
We read with interest the study of Herrmann et al. (1) that
examined the longitudinal left ventricular (LV) function, degree of
myocardial fibrosis, hemodynamic distinctions, and clinical out-
comes of symptomatic patients attributed to isolated aortic stenosis(AS). The patients were grouped and analyzed according to aortic
valve area, transvalvular gradient, and left ventricular ejection
fraction (LVEF); all patients with severe AS, regardless of trans-
valvular gradient, underwent aortic valve replacement.
We respectfully point out that the proportion of patients on
medical therapy with angiotensin-converting enzyme (ACE)
inhibitors, aldosterone antagonists, beta-blockers, and/or st-
atins at baseline and on follow-up 9 months later was not
reported. This information is important because these medica-
tions can potentially affect the outcomes being evaluated. We
would like to focus our comments regarding ACE inhibitor use,
specifically.
The preoperative use of ACE inhibitors can potentially affect
the outcome of the study by altering 2 factors considered for
patient assignment: transvalvular gradient and LVEF. Since resis-
tance in a series is additive, ACE inhibitors will decrease systemic
vascular resistance through arterial vasodilation, which in turn may
increase the transvalvular gradient (2). These agents are also
established reverse remodeling agents and can improve the LVEF
of patients with systolic dysfunction with long-term use. Although
previously thought to be a contraindication for patients with AS
because of the theoretical concern for hypotension, decreased
coronary perfusion, and renal insufficiency, several prospective
studies suggest that medical therapy with ACE inhibitors may be
safe (2,3). Dalsgaard et al. (4) recently demonstrated with a small
randomized controlled trial that the use of trandolapril among
patients with severe AS did not cause adverse outcomes or symptom-
atic hypotension. Over 8 weeks of follow-up, treatment with tran-
dolapril led to a decrease in LV end-systolic volume and N-terminal
pro–B-type natriuretic peptide, suggesting beneficial effect of ACE-
induced LV unloading (4). The study of Herrmann et al. (1) also
showed that the sickest patient subgroups (i.e., those with low-
gradient severe symptomatic AS, regardless of ejection fraction) have
the highest systemic vascular resistance and relatively preserved blood
pressure. It is plausible that medical therapy with ACE inhibitors
could potentially be used as a bridge to aortic valve surgery.
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